Glomeria Therapeutics, a Chieti, Italy-based company specialized in the development of medical devices for the treatment of nephropathy, raised over €1m in venture capital funding.
Backers included Spindial Group, Quadrivio sgr (via TT Venture) e Vertis sgr (via Vertis Venture).
The company intends to use the funds to to industrialize technologies and to finalize clinic studies leveraging Spindial’s expertise.
Led by CEO Andrea Zanella, Glomeria specializes in the research, development and commercialization of new medical devices for the treatment and cure of acute forms of nephropathy.
The company’s most advanced program focuses on the peritoneal dialysis in patients with chronic renal failure.
Its therapeutic platform includes biocompatible solutions for peritoneal dialysis (with low content of glucose degradation products), connection devices to limit the risk of peritonitis (DesmoPD), and a device for automated peritoneal dialysis capable of improving the management of the filling of the peritoneal cavity and increase the dialysis efficiency (SmartPD).